PMID- 35314166
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20220510
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 199
DP  - 2022 May
TI  - Potential role of mitochondria-associated endoplasmic reticulum membrane proteins 
      in diseases.
PG  - 115011
LID - S0006-2952(22)00105-8 [pii]
LID - 10.1016/j.bcp.2022.115011 [doi]
AB  - Mitochondria-associated endoplasmic reticulum membranes (MAMs) are dynamic 
      membrane coupling regions formed by the coupling of the mitochondrial outer 
      membrane and endoplasmic reticulum (ER). MAMs are involved in the mitochondrial 
      dynamics, mitophagy, Ca(2+) exchange, and ER stress. A large number of studies 
      indicate that many proteins are involved in the formation of MAMs, including 
      dynamic-related protein 1 (Drp1), DJ-1, PTEN-induced putative kinase 1 (PINK), 
      alpha-synuclein (alpha-syn), sigma-1 receptor (S1R), mitofusin-2 (Mfn2), presenilin-1 
      (PS1), protein kinase R (PKR)-like ER kinase (PERK), Parkin, Cyclophilin D 
      (CypD), glucose-related protein 75 (Grp75), FUN14 domain containing 1 (Fundc1), 
      vesicle-associated membrane-protein-associated protein B (VAPB), phosphofurin 
      acidic cluster sorting protein 2 (PACS-2), ER oxidoreductin 1 (Ero1), and 
      receptor expression-enhancing protein 1 (REEP1). These proteins play an important 
      role in the structure and functions of the MAMs. Abnormalities in these MAM 
      proteins further contribute to the occurrence and development of related 
      diseases, such as neurodegenerative diseases, non-alcoholicfattyliverdisease 
      (NALFD), type 2 diabetes mellitus (T2DM), and diabetic kidney (DN). In this 
      review, we introduce important proteins involved in the structure and the 
      functions of the MAMs. Furthermore, we effectively summarize major insights about 
      these proteins that are involved in the physiopathology of several diseases 
      through the effect on MAMs.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Mao, Hui
AU  - Mao H
AD  - Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor 
      Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation 
      Center for Molecular Target New Drug Study, University of South China, Hengyang 
      421001, China.
FAU - Chen, Wei
AU  - Chen W
AD  - Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor 
      Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation 
      Center for Molecular Target New Drug Study, University of South China, Hengyang 
      421001, China.
FAU - Chen, Linxi
AU  - Chen L
AD  - Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor 
      Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation 
      Center for Molecular Target New Drug Study, University of South China, Hengyang 
      421001, China. Electronic address: 1995001765@usc.edu.cn.
FAU - Li, Lanfang
AU  - Li L
AD  - Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor 
      Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation 
      Center for Molecular Target New Drug Study, University of South China, Hengyang 
      421001, China. Electronic address: 2005001782@usc.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220318
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (REEP1 protein, human)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Endoplasmic Reticulum/metabolism
MH  - Humans
MH  - Membrane Transport Proteins/metabolism
MH  - Mitochondria/metabolism
MH  - Mitochondrial Membranes/metabolism
MH  - Mitochondrial Proteins/metabolism
OTO - NOTNLM
OT  - Diabetic kidney
OT  - Mitochondria-associated endoplasmic reticulum membranes
OT  - Neurodegenerative diseases
OT  - Non-alcoholic fatty liver disease
OT  - Type 2 diabetes mellitus
EDAT- 2022/03/23 06:00
MHDA- 2022/04/29 06:00
CRDT- 2022/03/22 05:34
PHST- 2021/12/24 00:00 [received]
PHST- 2022/02/26 00:00 [revised]
PHST- 2022/03/15 00:00 [accepted]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
PHST- 2022/03/22 05:34 [entrez]
AID - S0006-2952(22)00105-8 [pii]
AID - 10.1016/j.bcp.2022.115011 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2022 May;199:115011. doi: 10.1016/j.bcp.2022.115011. Epub 2022 
      Mar 18.